ATAI Life Sciences N.V. (ATAI) financial statements (2022 and earlier)
Company profile
| Business Address |
180 VARICK STREET NEW YORK, NY 10014 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 362,266 | 430,308 | 453,622 | ||
| Cash and cash equivalents | 362,266 | 430,308 | 453,622 | ||
| Receivables | 913 | ||||
| Prepaid expense | 7,713 | 6,915 | 416 | ||
| Other current assets | 756 | 461 | 111 | ||
| Other undisclosed current assets | 3,434 | 4,175 | 3,437 | ||
| Total current assets: | 375,082 | 441,859 | 457,586 | ||
| Noncurrent Assets | |||||
| Property, plant and equipment | 149 | 138 | 331 | ||
| Long-term investments and receivables | 31,594 | 34,034 | 40,469 | ||
| Long-term investments | 27,759 | 29,342 | 35,887 | ||
| Accounts and financing receivable, after allowance for credit loss | 908 | 1,388 | |||
| Due from related parties | 3,835 | 3,784 | 3,194 | ||
| Other noncurrent assets | 7,341 | 1,262 | 689 | ||
| Other undisclosed noncurrent assets | 6,816 | 6,886 | |||
| Total noncurrent assets: | 39,084 | 42,250 | 48,375 | ||
| TOTAL ASSETS: | 414,166 | 484,109 | 505,961 | ||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 20,833 | 15,049 | 14,026 | ||
| Accounts payable | 6,004 | 1,974 | 6,202 | ||
| Accrued liabilities | 14,829 | 13,075 | 7,824 | ||
| Deferred revenue | 180 | 120 | |||
| Debt | 38 | 39 | |||
| Business combination, contingent consideration, liability | 51 | 50 | |||
| Other liabilities | 51 | ||||
| Total current liabilities: | 20,935 | 15,317 | 14,185 | ||
| Noncurrent Liabilities | |||||
| Long-term debt and lease obligation | 743 | 800 | 1,176 | ||
| Long-term debt, excluding current maturities | 743 | 800 | 1,176 | ||
| Liabilities, other than long-term debt | 6,529 | 5,232 | 5,705 | ||
| Other liabilities | 4,097 | 3,285 | 3,239 | ||
| Business combination, contingent consideration, liability | 2,432 | 1,947 | 2,466 | ||
| Total noncurrent liabilities: | 7,272 | 6,032 | 6,881 | ||
| Total liabilities: | 28,207 | 21,349 | 21,066 | ||
| Stockholders' equity | |||||
| Stockholders' equity attributable to parent | 376,908 | 453,186 | 474,850 | ||
| Common stock | 18,002 | 17,870 | 17,299 | ||
| Additional paid in capital | 725,045 | 709,475 | 691,382 | ||
| Accumulated other comprehensive income (loss) | (8,336) | (5,233) | 3,937 | ||
| Accumulated deficit | (357,803) | (268,926) | (237,768) | ||
| Stockholders' equity attributable to noncontrolling interest | 9,051 | 9,574 | 10,045 | ||
| Total stockholders' equity: | 385,959 | 462,760 | 484,895 | ||
| TOTAL LIABILITIES AND EQUITY: | 414,166 | 484,109 | 505,961 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|
| Revenues | 230 | 266 | ||
| Gross profit: | 230 | 266 | ||
| Operating expenses | (45,405) | (33,627) | (61,319) | |
| Operating loss: | (45,175) | (33,361) | (61,319) | |
| Nonoperating income (expense) | (3,404) | 6,887 | (5,982) | |
| Foreign currency transaction gain, before tax | 3,035 | 6,462 | ||
| Other nonoperating income (expense) | 62 | (29) | (2,676) | |
| Loss from continuing operations before equity method investments, income taxes: | (48,579) | (26,474) | (67,301) | |
| Loss from equity method investments | (49,115) | (4,800) | (2,937) | |
| Other undisclosed income from continuing operations before income taxes | 58,555 | |||
| Loss from continuing operations before income taxes: | (39,139) | (31,274) | (70,238) | |
| Income tax expense (benefit) | 4,421 | (368) | (58) | |
| Loss before gain (loss) on sale of properties: | (34,718) | (31,642) | (70,296) | |
| Other undisclosed net income (loss) | (58,555) | 16,923 | ||
| Net loss: | (93,273) | (31,642) | (53,373) | |
| Net income attributable to noncontrolling interest | 4,396 | 484 | 4,912 | |
| Net loss available to common stockholders, diluted: | (88,877) | (31,158) | (48,461) | |
Comprehensive Income ($ in thousands)
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | ||
|---|---|---|---|---|
| Net loss: | (93,273) | (31,642) | (53,373) | |
| Other undisclosed comprehensive income (loss) | (3,081) | (9,158) | 2,110 | |
| Comprehensive loss: | (96,354) | (40,800) | (51,263) | |
| Comprehensive income, net of tax, attributable to noncontrolling interest | 4,398 | 472 | 4,762 | |
| Comprehensive loss, net of tax, attributable to parent: | (91,956) | (40,328) | (46,501) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.